about
Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damageMorphine and clonidine combination therapy improves therapeutic window in mice: synergy in antinociceptive but not in sedative or cardiovascular effectsCosts and benefits of multiple resistance to insecticides for Culex quinquefasciatus mosquitoes.Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapyAttenuation of morphine antinociceptive tolerance by a CB(1) receptor agonist and an NMDA receptor antagonist: Interactive effects.Protein kinase C mediates the synergistic interaction between agonists acting at alpha2-adrenergic and delta-opioid receptors in spinal cord.Satiety factor oleoylethanolamide recruits the brain histaminergic system to inhibit food intakeEffects of celecoxib and ly117018 combination on human breast cancer cells in vitro.Ligand requirements for involvement of PKCε in synergistic analgesic interactions between spinal μ and δ opioid receptors.Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.Anticonflict and reinforcing effects of triazolam + pregnanolone combinations in rhesus monkeys.Serotonin receptor activity is necessary for olfactory learning and memory in Drosophila melanogasterCombined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.Resistance analysis and characterization of a thiazole analogue, BP008, as a potent hepatitis C virus NS5A inhibitorDifferential interactions engendered by benzodiazepine and neuroactive steroid combinations on schedule-controlled responding in rats.Revisiting the isobole and related quantitative methods for assessing drug synergismInteractions between drugs and occupied receptors.Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems.Synergistic GABA-enhancing therapy against seizures in a mouse model of Dravet syndrome.Combination of extracts from Aristolochia cymbifera with streptomycin as a potential antibacterial drugSynergistic interaction between metformin and sulfonylureas on diclofenac-induced antinociception measured using the formalin test in rats.Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactionsNew Insights toward Colorectal Cancer Chemotherapy Using Natural Bioactive Compounds.The determination and application of fixed-dose analgesic combinations for treating multimodal pain.Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo.Evaluation of the cardiotoxicity and resuscitation of rats of a newly developed mixture of a QX-314 analog and levobupivacaine.Docosahexaenoic acid: a natural powerful adjuvant that improves efficacy for anticancer treatment with no adverse effects.Environmentally oriented models and methods for the evaluation of drug × drug interaction effects.Pharmacodynamic interaction models in pediatric anesthesia.Supra-Additive Interaction of Docosahexaenoic Acid and Naproxen and Gastric Safety on the Formalin Test in Rats.Antinociceptive synergistic interaction between Achillea millefolium and Origanum vulgare L. extract encapsulated in liposome in rat.Isobolographic Analyses of Proglumide-Celecoxib Interaction in Rats with Painful Diabetic Neuropathy.Isobologram analysis of triple therapies.CJY, an isoflavone, interacts with ATPase of P-glycoprotein in the rat brain microvessel endothelial cells (RBMECs).The Antinociceptive Effect of a Tapentadol-Ketorolac Combination in a Mouse Model of Trigeminal Pain is Mediated by Opioid Receptors and ATP-Sensitive K+ Channels.Synergistic combinations of the dual enkephalinase inhibitor PL265 given orally with various analgesic compounds acting on different targets, in a murine model of cancer-induced bone pain.Synergistic interaction between diclofenac and pyrilamine on nociception, inflammation, and gastric damage in rats.On the quantitation of an agonist with dual but opposing components of action: application to vascular endothelial relaxationThe hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitorsIsobolographic Analysis of the Interaction Between Tapentadol and Ketorolac in a Mouse Model of Visceral Pain.
P2860
Q25257535-EB571A76-A50F-4B28-8F98-353565B411B9Q28543670-19175282-D38E-48B3-8174-3C8C3F1AF11DQ33327304-531A600A-56E6-4685-85D9-B5BB089D93B7Q33577548-B8E7ADB9-54A1-4486-A387-FE63E02CE05AQ33618200-333205F2-F0E4-4448-B7AC-A332D7375181Q33643934-C6F3C032-E5D0-415D-AEDB-05E202C4FDE4Q34025489-B80615A1-F211-42D2-AFFF-7A3AED631134Q34908885-36C0E814-2047-4665-B367-E5EFC01E82C7Q34939914-795EF425-8F87-403B-A4C5-34B9D1EA9558Q34973753-BE2A29D6-E9D7-47D5-8474-84FFB1C46817Q35003075-49DB3F39-67FA-4EE2-AC92-3A45776D7843Q35194603-C2A417B2-A6BD-494D-BD8C-A45A50932118Q35505109-3F1CFE89-BAA6-4488-A543-093CFC5B06EFQ35666596-D589BCBD-9EC2-4A67-BB13-BDA5B1A6E9F5Q36054271-9E132540-32CC-45F1-A4F0-9B8365F293EAQ36057956-DFE23345-CE9C-45F1-BFE3-1C28F9CA97CAQ36099198-01479730-D6C9-4B25-A4BE-C535C9C615EBQ36558519-55443128-4688-4178-A454-8FCB140A164FQ36776559-D7605916-BDBD-4871-9419-75373D86E2C7Q37165462-5ADF3D91-5820-4A71-BA9F-7DDAE8035FF8Q37247791-C4A9712C-13BF-4D01-868D-901EAFACE63DQ37263780-92E1F664-D8EC-42F9-87B1-EBF55769E04EQ37697414-A907DEAF-30DC-47F7-83F2-0F8921F36FC6Q37719166-9A846E86-26ED-4A41-9205-3CBD1C65A0ADQ37726102-87FEB6B5-22D5-4E8B-816A-A08DD7DEFD6AQ37733193-8AF348E7-A461-4D1A-BBC3-7102580725A9Q37950943-213C6B5D-F695-4C02-ACD3-E3BDAE700AFAQ38307252-9053225B-01CD-46A7-B3A7-9131B9562F48Q38560451-3266855C-7B3F-4CBF-9AB7-43234EA7E5D2Q38644187-2523EB2E-A2ED-477A-AA18-BFB9ABCBE2ACQ38673599-00D07A19-2DA0-4849-B5CD-0DB265143D7EQ38859610-7CF65C41-AC52-4D2E-A38E-EF7F6D0DCF42Q39065896-5F020071-BE33-41A8-972F-3C246CA14783Q39088427-3D90CEFE-BFD7-4CF8-BCB3-9FF8E35595D0Q39093095-00A6B370-D846-418B-A48B-444F955582FEQ39150711-33EE9270-F25B-4954-8E43-788A39039655Q39199282-B327CEE3-F14C-4A3F-916F-BE7CE90DA65BQ39227660-FF2C7EE1-6106-4C7E-9D45-32A65DF7C89EQ39702043-FE65BB6D-F273-424A-BC66-6ACD7182898CQ39774013-3771EAB4-F93E-4153-A862-4D20EEE61887
P2860
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
The interaction index: a measure of drug synergism.
@en
The interaction index: a measure of drug synergism.
@nl
type
label
The interaction index: a measure of drug synergism.
@en
The interaction index: a measure of drug synergism.
@nl
prefLabel
The interaction index: a measure of drug synergism.
@en
The interaction index: a measure of drug synergism.
@nl
P1433
P1476
The interaction index: a measure of drug synergism.
@en
P304
P356
10.1016/S0304-3959(02)00041-6
P407
P577
2002-07-01T00:00:00Z